Male Infertility (Asthenozoospermia) CRISPR Knockout Models

Male infertility affects approximately 7% of all men globally, with asthenozoospermia (reduced sperm motility) being a leading cause, present in about 40-50% of male infertility cases (WHO, 2023). Asthenozoospermia is defined by the World Health Organization as less than 32% progressive motility in semen analysis. The condition has significant clinical impact, contributing to over 30 million infertile men worldwide. Risk factors include genetic mutations, oxidative stress, varicocele, infections, and environmental toxins. No FDA-approved pharmacological treatments exist; assisted reproductive technologies (ART) such as intracytoplasmic sperm injection (ICSI) remain the primary intervention, with variable success rates (NCI, 2024).

Asthenozoospermia is an ideal model for mechanistic studies of sperm flagellar function, energy metabolism, and calcium signaling. The condition encompasses several subtypes, including primary ciliary dyskinesia (PCD), mitochondrial sheath defects, and flagellar axonemal abnormalities. Public datasets from the Human Protein Atlas and NCBI Gene provide transcriptomic and proteomic data on sperm-specific genes. Key open questions include the molecular basis of idiopathic asthenozoospermia, the role of epigenetic modifications, and the development of non-hormonal therapies to improve sperm motility.

The pathogenesis of asthenozoospermia involves several key pathways:

• • Calcium Signaling Pathway: Calcium influx via CATSPER channels is essential for hyperactivated motility. Disruption leads to reduced flagellar beat frequency.
• • cAMP/PKA Pathway: Cyclic AMP-dependent protein kinase A regulates flagellar phosphorylation and motility. Mutations in ADCY10 or PRKACA impair signaling.
• • Mitochondrial Oxidative Phosphorylation: Sperm motility requires ATP from mitochondrial respiration. Defects in electron transport chain complexes reduce energy production.
• • Flagellar Axoneme Assembly: Dynein arm proteins (DNAH1, DNAH5) and radial spoke proteins (RSPH1, RSPH9) are critical for axonemal structure. Mutations cause structural flagellar defects.

Data from ClinVar, NCBI Gene, and COSMIC (2024).

Key deregulated networks in asthenozoospermia include:

• • Calcium Signaling Network: CATSPER1-4 channels, CALM1, CAMK4, and PPP3CC. Mutations in any node disrupt calcium-dependent motility.
• • cAMP/PKA Network: ADCY10, PRKACA, PRKAR1A, and PDE4A. Reduced cAMP levels decrease PKA activity and flagellar phosphorylation.
• • Mitochondrial Energy Network: NDUFS1, SDHA, ATP5A1, and UQCRC1. Defects reduce ATP synthesis, impairing sustained motility.
• • Axoneme Assembly Network: DNAH1, DNAH5, DNAI1, RSPH1, and SPEF2. Mutations cause structural abnormalities in the flagellar axoneme.

Organoid models derived from human testicular biopsies (spermatogonial stem cell organoids) offer advantages for studying spermatogenesis and flagellar development in a 3D environment, enabling long-term culture and differentiation.

• • Genetically Engineered Mouse Models (GEMM): CATSPER1 knockout mice show complete infertility with immotile sperm. DNAH1 mutant mice exhibit flagellar defects.
• • Induced Models: Administration of cyclophosphamide or busulfan induces testicular toxicity and asthenozoospermia in rodents.
• • Patient-Derived Xenografts (PDX): Not commonly used for male infertility; testicular tissue xenografts in immunodeficient mice allow study of human spermatogenesis.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise mutations in genes associated with asthenozoospermia. For example, CATSPER1 knockout in HEK293T cells allows functional studies of calcium signaling. DNAH1 knockout in HCT116 cells models flagellar structural defects. AKAP4 knockout in K562 cells helps investigate fibrous sheath assembly. Commercially available, sequence-verified isogenic models accelerate research by providing consistent, validated tools for drug screening and mechanistic studies. These models are available from commercial sources and can be custom-engineered for specific mutations.

CRISPR knockout and knock-in lines are used to validate the role of candidate genes in sperm motility. For example, CATSPER1 knockout in HEK293T cells confirms the requirement of this channel for calcium influx. DNAH1 knockout in HCT116 cells demonstrates the necessity of dynein arms for flagellar movement. These models enable high-throughput functional screens to identify novel motility-related genes.

Isogenic pairs (wild-type vs. knockout) are used in drug screening to identify compounds that restore motility in mutant cells. For instance, CATSPER1 knockout cells can be used to screen for calcium channel agonists. Resistance modeling involves exposing knockout cells to potential therapeutics to assess compensatory mechanisms.

CRISPR synthetic lethality screens identify genes that, when knocked out, are lethal only in the context of a specific mutation (e.g., DNAH1 deficiency). This approach reveals potential therapeutic targets and biomarkers for patient stratification in ART outcomes.